Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com
by Teresa Graham · The Cerbat GemStockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research note released on Monday. The firm issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
BTX stock opened at $0.90 on Monday. The stock has a market capitalization of $52.89 million, a price-to-earnings ratio of -0.40 and a beta of 4.61. The business’s fifty day moving average price is $1.42 and its two-hundred day moving average price is $1.75. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.
Brooklyn ImmunoTherapeutics Company Profile
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- What are earnings reports?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?